rabbit polyclonal antibody against il 8  (Bioss)

Journal: Molecular Biology Reports

Article Title: Assessment of atherosclerotic plaques in the rabbit abdominal aorta with interleukin-8 monoclonal antibody-targeted ultrasound microbubbles

doi: 10.1007/s11033-012-2382-5

Figure Lengend Snippet: Light micrograph of SonoVue microbubbles. a Non-conjugated SonoVue microbubbles. b IL-8 monoclonal antibody-conjugated SonoVue microbubbles (×100)

Article Snippet: After the addition of rabbit polyclonal antibody against IL-8 (Bioss, Beijing, China), the sections were incubated at room temperature for 60 min, washed with PBS, and stained using a MaxvisionTM2 HRP-Polymer anti-Mouse IHC Kit (Maxim Biotech Inc. Fuzhou, China).

Techniques:

Journal: Molecular Biology Reports

Article Title: Assessment of atherosclerotic plaques in the rabbit abdominal aorta with interleukin-8 monoclonal antibody-targeted ultrasound microbubbles

doi: 10.1007/s11033-012-2382-5

Figure Lengend Snippet: Light micrograph of the mixture of SonoVue microbubbles and goat anti-mouse serum. a Non-conjugated microbubbles (×100). b Non-conjugated microbubbles (×400). c IL-8 monoclonal antibody-conjugated microbubbles (×100). d IL-8 monoclonal antibody-conjugated microbubbles (×400)

Article Snippet: After the addition of rabbit polyclonal antibody against IL-8 (Bioss, Beijing, China), the sections were incubated at room temperature for 60 min, washed with PBS, and stained using a MaxvisionTM2 HRP-Polymer anti-Mouse IHC Kit (Maxim Biotech Inc. Fuzhou, China).

Techniques:

Journal: Molecular Biology Reports

Article Title: Assessment of atherosclerotic plaques in the rabbit abdominal aorta with interleukin-8 monoclonal antibody-targeted ultrasound microbubbles

doi: 10.1007/s11033-012-2382-5

Figure Lengend Snippet: Immunofluorescence image of IgG-FITC-stained SonoVue microbubbles. a No fluorescence was observed on the surface of non-conjugated SonoVue microbubbles. b Bright-green fluorescence can be observed on the surface of IL-8-conjugated SonoVue microbubbles (×400). (Color figure online)

Article Snippet: After the addition of rabbit polyclonal antibody against IL-8 (Bioss, Beijing, China), the sections were incubated at room temperature for 60 min, washed with PBS, and stained using a MaxvisionTM2 HRP-Polymer anti-Mouse IHC Kit (Maxim Biotech Inc. Fuzhou, China).

Techniques: Immunofluorescence, Staining, Fluorescence

Journal: Molecular Biology Reports

Article Title: Assessment of atherosclerotic plaques in the rabbit abdominal aorta with interleukin-8 monoclonal antibody-targeted ultrasound microbubbles

doi: 10.1007/s11033-012-2382-5

Figure Lengend Snippet: Representative ultrasound images of the atherosclerotic plaques in the rabbit abdominal aorta. a Two-dimensional image showing a plaque ( large arrow ); a soft plaque was invisible ( small arrow ). b Contrast ultrasound imaging with normal microbubbles showing two plaques with stronger echo compared with the two-dimensional view. The enhancement of the echo was more apparent for the soft plaque ( small arrow ). c Contrast ultrasound imaging with IL-8-targeted microbubbles showing two plaques with a markedly stronger echo compared with normal contrast ultrasound

Article Snippet: After the addition of rabbit polyclonal antibody against IL-8 (Bioss, Beijing, China), the sections were incubated at room temperature for 60 min, washed with PBS, and stained using a MaxvisionTM2 HRP-Polymer anti-Mouse IHC Kit (Maxim Biotech Inc. Fuzhou, China).

Techniques: Imaging

Journal: Molecular Biology Reports

Article Title: Assessment of atherosclerotic plaques in the rabbit abdominal aorta with interleukin-8 monoclonal antibody-targeted ultrasound microbubbles

doi: 10.1007/s11033-012-2382-5

Figure Lengend Snippet: Sequential ultrasound images of IL-8-targeted imaging for an atherosclerotic plaque of the rabbit abdominal aorta. a Conventional two-dimensional view. b – g Sequential targeted CEU view: b 3.8 s post-contrast agent injection, c : 4.3 s post-contrast agent injection, d 4.9 s post-contrast agent injection; e 9.8 s post-contrast agent injection, f 68 s post-contrast agent injection, g 176 s post-contrast agent injection

Article Snippet: After the addition of rabbit polyclonal antibody against IL-8 (Bioss, Beijing, China), the sections were incubated at room temperature for 60 min, washed with PBS, and stained using a MaxvisionTM2 HRP-Polymer anti-Mouse IHC Kit (Maxim Biotech Inc. Fuzhou, China).

Techniques: Imaging, Injection

Journal: Molecular Biology Reports

Article Title: Assessment of atherosclerotic plaques in the rabbit abdominal aorta with interleukin-8 monoclonal antibody-targeted ultrasound microbubbles

doi: 10.1007/s11033-012-2382-5

Figure Lengend Snippet: The time-intensity curves of contrast ultrasound imaging with normal microbubbles ( a ) and IL-8-targeted microbubbles ( b ). The yellow , blue and red curves indicate the intensity of the lumen, intima and plaques, respectively. (Color figure online)

Article Snippet: After the addition of rabbit polyclonal antibody against IL-8 (Bioss, Beijing, China), the sections were incubated at room temperature for 60 min, washed with PBS, and stained using a MaxvisionTM2 HRP-Polymer anti-Mouse IHC Kit (Maxim Biotech Inc. Fuzhou, China).

Techniques: Imaging

Journal: Molecular Biology Reports

Article Title: Assessment of atherosclerotic plaques in the rabbit abdominal aorta with interleukin-8 monoclonal antibody-targeted ultrasound microbubbles

doi: 10.1007/s11033-012-2382-5

Figure Lengend Snippet: Immunohistochemical expression of IL-8 in atherosclerotic plaques in the rabbit abdominal aorta. Brown -stained area indicates positive IL-8 expression. ( a ×40; b ×200). (Color figure online)

Article Snippet: After the addition of rabbit polyclonal antibody against IL-8 (Bioss, Beijing, China), the sections were incubated at room temperature for 60 min, washed with PBS, and stained using a MaxvisionTM2 HRP-Polymer anti-Mouse IHC Kit (Maxim Biotech Inc. Fuzhou, China).

Techniques: Immunohistochemical staining, Expressing, Staining

Journal: Clinical and Experimental Gastroenterology

Article Title: Toll-Like Receptor 3 as a Recurrence Risk Factor and a Potential Molecular Therapeutic Target in Colorectal Cancer

doi: 10.2147/CEG.S252157

Figure Lengend Snippet: Treatment of SW480 with poly I:C induces the expression of CCL2, CCL5, and IL-8. ( A – C ) SW480 was treated with 30 µg/mL poly I:C for up to 24h, and RNA was extracted. The expression of CCL2, CCL5, and IL-8 mRNA was examined using quantitative real-time RT-PCR analysis. Poly I:C induced these mRNA in a time-dependent manner, and the expression peaked at 4h. ( D – F ) The cells were treated with 0–50 µg/mL poly I:C for 4h and quantitative real-time RT-PCR was performed. Treatment of SW480 with poly I:C induced the expression of these mRNA in a concentration-dependent manner. ( G – I ) The cells were treated with poly I:C as in ( A – C ), and the medium was collected. The concentration of CCL2, CCL5, and IL-8 proteins was measured using ELISAs. Poly I:C induced expression of CCL2, CCL5, and IL-8 proteins in SW480. *p-value < 0.01; Student’s t -test.

Article Snippet: Following antigen retrieval, tissue samples were incubated for 15 min with mouse monoclonal antibodies against TLR3 (NBP2-24875, Novus Biologicals, Centennial, CO) at 1:30 dilution, for 20 min with rabbit polyclonal antibodies against C-C motif chemokine ligand 2 (CCL2) (HPA019163, Sigma-Aldrich, St. Louis, MO) at 1:50 dilution, 20 min with goat polyclonal antibodies against C-C motif chemokine ligand 5 (CCL5) (AF-278-NA, R&D Systems, Minneapolis, MN) at 1:25 dilution and for 20 min with rabbit polyclonal antibodies against IL-8 (AHC0881, Thermo Fisher Scientific, Waltham, MA) at 1:100 dilution.

Techniques: Expressing, Quantitative RT-PCR, Concentration Assay

Journal: Clinical and Experimental Gastroenterology

Article Title: Toll-Like Receptor 3 as a Recurrence Risk Factor and a Potential Molecular Therapeutic Target in Colorectal Cancer

doi: 10.2147/CEG.S252157

Figure Lengend Snippet: TLR3 is involved in the expression CCL2, CCL5, and IL-8 induced by poly I:C. SW480 were transfected with siRNA against TLR3 or non-silencing control siRNA. After 48 h, the cells were treated with poly I:C. After further incubation for 4 h and 24 h, RNA was extracted, and the conditioned medium was collected. The expressions of mRNA ( A – C ) and protein ( D – F ) for CCL2, CCL5, and IL-8 were estimated using quantitative real-time RT-PCR and ELISA, respectively. Expression of all of CCL2, CCL5, and IL-8 was upregulated by poly I:C and siRNA against TLR3 inhibited the upregulation of these molecules. *p-value < 0.01; Student’s t -test.

Article Snippet: Following antigen retrieval, tissue samples were incubated for 15 min with mouse monoclonal antibodies against TLR3 (NBP2-24875, Novus Biologicals, Centennial, CO) at 1:30 dilution, for 20 min with rabbit polyclonal antibodies against C-C motif chemokine ligand 2 (CCL2) (HPA019163, Sigma-Aldrich, St. Louis, MO) at 1:50 dilution, 20 min with goat polyclonal antibodies against C-C motif chemokine ligand 5 (CCL5) (AF-278-NA, R&D Systems, Minneapolis, MN) at 1:25 dilution and for 20 min with rabbit polyclonal antibodies against IL-8 (AHC0881, Thermo Fisher Scientific, Waltham, MA) at 1:100 dilution.

Techniques: Expressing, Transfection, Incubation, Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay

Journal: Clinical and Experimental Gastroenterology

Article Title: Toll-Like Receptor 3 as a Recurrence Risk Factor and a Potential Molecular Therapeutic Target in Colorectal Cancer

doi: 10.2147/CEG.S252157

Figure Lengend Snippet: Immunohistochemistry for CCL2, CCL5 and IL-8 in TLR3-positive CRC in surgical specimens. In TLR3-positive CRC specimens, CCL2 was partially stained in the cytoplasm of tumor cells (arrow head). CCL5 was uniformly stained in the cytoplasm of the tumor cells and was also found in the surrounding stromal cells. IL-8 was uniformly and faintly stained in the cytoplasm of tumor cells and also stained in stromal cells (Magnification: 200×).

Article Snippet: Following antigen retrieval, tissue samples were incubated for 15 min with mouse monoclonal antibodies against TLR3 (NBP2-24875, Novus Biologicals, Centennial, CO) at 1:30 dilution, for 20 min with rabbit polyclonal antibodies against C-C motif chemokine ligand 2 (CCL2) (HPA019163, Sigma-Aldrich, St. Louis, MO) at 1:50 dilution, 20 min with goat polyclonal antibodies against C-C motif chemokine ligand 5 (CCL5) (AF-278-NA, R&D Systems, Minneapolis, MN) at 1:25 dilution and for 20 min with rabbit polyclonal antibodies against IL-8 (AHC0881, Thermo Fisher Scientific, Waltham, MA) at 1:100 dilution.

Techniques: Immunohistochemistry, Staining

Journal: British Journal of Cancer

Article Title: Clinicopathological and prognostic significance of interleukin-8 expression and its relationship to KRAS mutation in lung adenocarcinoma

doi: 10.1038/bjc.2014.110

Figure Lengend Snippet: Cox regression analysis for survival in 119 patients with lung adenocarcinomas

Article Snippet: A rabbit polyclonal antibody against IL-8 (Abcam, Cambridge, MA, USA) and a mouse monoclonal antibody against CD34 (Nichirei, Tokyo, Japan) were used.

Techniques: Mutagenesis, Expressing

Journal: PLoS ONE

Article Title: Lymphangiogenesis and Angiogenesis in Abdominal Aortic Aneurysm

doi: 10.1371/journal.pone.0089830

Figure Lengend Snippet: A , Elastica van Gieson staining of abdominal aortic aneurysm (AAA). Immunohistochemistry for podoplanin ( B ) and macrophages ( C ), CD19 ( E ), and myeloperoxidase (MPO) of the AAA wall. B , Lymphatic microvessels in the intima/media of the AAA (red dotted line encircling lymphatic microvessels). C , Macrophages infiltration around/within lymphatic microvessels in the intima/media or in adventitia (red square: macrophages in intima/media, black square: macrophages in adventitia). D , CD3-positive T cells infiltration around/within lymphatic microvessels in the intima/media or in adventitia. E , CD19-positive B cells infiltration around/within lymphatic microvessels in the intima/media or in adventitia. F , MPO-positive neutrophils infiltration in the intima/media or in adventitia. G–P , Double immunofluorescence staining of macrophages infiltrating the intima/media (In) and adventitia (Ad). G–P , Macrophage: green, CD11b ( G )/LYVE-1 ( H )/VEGF-C ( I )/MMP-9 ( J )/TGF-β1 ( K )/IL-4 ( L )/IL-8 ( M )/MIP-1α ( N )/IFN-γ ( O )/MCP-1 ( P ): red, DAPI: blue. LYVE-1, VEGF-C, MMP-9, TGF-β1, IL-4, IL-8, MIP-1α, and MCP-1 were expressed in the CD11b-positive macrophages in the intima/media, but not by macrophages in adventitia. Q , Double immunofluorescence staining of T-cells in intima/media and inflammatory cytokines. CD3: green, VEGF-C/MMP-9/TGF-β1/IL-4/IL-8/MIP-1α/IFN-γ/MCP-1: red, DAPI: blue. TGF-β1, IL-4, and IFN-γ were expressed in CD3-positive T lymphocytes in the intima/media. R , Double immunofluorescence staining of B lymphocytes in the intima/media and inflammatory cytokines. CD19: green, VEGF-C/MMP-9/TGF-β1/IL-4/IL-8/MIP-1α/IFN-γ/MCP-1: red, DAPI: blue. These inflammatory cytokines were not expressed in CD19-positive B lymphocytes. S , Double immunofluorescence staining of neutrophils in intima/media and inflammatory cytokines. MPO: green, VEGF-C/MMP-9/TGF-β1/IL-4/IL-8/MIP-1α/IFN-γ/MCP-1: red, DAPI: blue. These inflammatory cytokines were not expressed in MPO-positive neutrophils. Scale bars indicated 100 µm ( A–F ) and 10 µm ( G–S ).

Article Snippet: The following primary antibodies were used: mouse monoclonal antibody against podoplanin (1∶200, DakoCytomation, Glostrup, Denmark), rabbit polyclonal antibody against Prox-1 (1∶2000, Millipore, MA, USA), rabbit polyclonal antibody against the N-terminus of human alpha smooth muscle isoform of actin (1∶25, Thermo Scientific Japan, Tokyo, Japan), mouse monoclonal antibody against human HIF-1α (1∶100, Novus Biologicals, CO, USA), rabbit monoclonal antibody against human CD11b (1∶250, Millipore, MA, USA), mouse monoclonal antibody against human macrophages (1∶100, AbD Serotec, Oxford, UK), rabbit polyclonal antibody against human LYVE-1 (1∶100, Relia Tech, Braunschweig, Germany), rabbit polyclonal antibody against human VEGF-C (1∶50, Abcam, Tokyo, Japan), rabbit polyclonal antibody against human matrix metalloproteinase (MMP)-9 (1∶100, Abnova, Taipei, Taiwan), mouse monoclonal antibody against human CD3 (1∶100, LifeSpan Biosciences, Seattle, WA), mouse monoclonal antibody against human CD19 (1∶50, Santa Cruz Biotechnology, CA, USA), mouse monoclonal antibody against human myeloperoxidase (MPO) (1∶50, Santa Cruz Biotechnology, CA, USA), rabbit polyclonal antibody against transforming growth factor beta-1 (TGF-β1) (1∶50, Abbiotec, CA, USA), rabbit polyclonal antibody against human interleukin-4 (IL-4) (1∶50, Biozol, Munich, Germany), rabbit polyclonal antibody against human interleukin-8 (IL-8) (1∶50, Abnova, Taipei, Taiwan), rabbit polyclonal antibody against human macrophage inflammatory protein-1α (MIP-1α) (1∶50, Spring bioscience, CA, USA), rabbit polyclonal antibody against human interferon-γ (IFN-γ) (1∶50, Santa Cruz Biotechnology, CA, USA), and rabbit polyclonal antibody against human monocyte chemotactic protein-1 (MCP-1) (1∶50, Abnova, Taipei, Taiwan).

Techniques: Staining, Immunohistochemistry, Double Immunofluorescence Staining